A severe case of papulovesicular exanthema with rhabdomyolysis after coronavirus disease 2019 heterologous booster vaccination

Editor

A 66-year-old Japanese man was admitted for an emergency with skin rashes and muscle pain of his extremities. He had high fever over 39°C and difficulty in moving. He was taking bezafibrate 200 mg/day for hyperlipidemia for 3 months and received the third dose booster mRNA-1273 vaccine (Moderna) 8 months after the second vaccination with BNT162b1 (BioNTech-Pfizer). The present symptoms appeared 5 days after the third vaccination. At the second vaccination, he experienced no severe adverse events (AEs) other than temporary fever. On physical examination, widespread edematous and erythematous papulovesicles were seen on his trunk and extremities (Fig. 1a).

Laboratory examination revealed elevated serum levels of creatine kinase (CK) at 801 U/L (normal range 59–248 U/L), myoglobin at 839 ng/mL (<154.9 ng/mL) and creatinine at 2.27 mg/dL (<1.2 mg/dL). His urine was reddish brown due to

![Figure 1](https://example.com/figure1.png)

**Figure 1** (a) Numerous widespread edematous and erythematous papulovesicles. (b) A reddish-brown myoglobinuria. (c) Erythematous papules on the abdomen. (d) Spongiosis of the epidermis and papillary dermal edema (HE, original magnification ×40). (e) Inflammatory infiltrates of lymphocytic with eosinophils in the vicinity of the small vessels in the upper dermis (HE, ×100).
myoglobinuria (Fig. 1b). Electrocardiogram and echocardiography demonstrated no findings of myocarditis. A biopsy from his abdomen (Fig. 1c) showed epidermal spongiosis, papillary oedema and perivascular lymphocytic infiltration with eosinophils in the upper dermis (Fig. 1d,e). We started oral prednisolone, 55 mg/day, and adequate fluid resuscitation and discontinued bezafibrate, resulting in rapid improvement of his cutaneous lesions and renal function in 5 days. CK and creatinine returned to normal. Both patch test and drug-induced lymphocyte stimulation test for bezafibrate were negative. Our diagnosis was papulovesicular-type vaccine-related eruption of papules and plaques (V-REPP) with rhabdomyolysis induced by the COVID-19 vaccine.

Various COVID-19 vaccine-related cutaneous reactions have been reported. The acronym of the descriptive terms, V-REPP, was proposed for robust papules with overlying crust to pink papules with scales as seen in the present case. This type accounts for 3.0% of overall cutaneous reaction (n = 1364).1 There are several case reports of rhabdomyolysis due to drugs or vaccines, most commonly to influenza vaccine, statins and fibrates.2 According to the Vaccine Adverse Event Reporting System of the Centers for Disease Control and Prevention, 214 cases of rhabdomyolysis after COVID-19 vaccination were reported as of 14 January 2022.3 Kamura et al.4 reported a Japanese case of fatal thrombotic microangiopathy with rhabdomyolysis after the first dose of mRNA-1273. They suggested the involvement of an immunological mechanism such as vaccine-induced complement activation syndrome. To the best of our knowledge, there has been no report of concomitant development of rhabdomyolysis and papulovesicular-type V-REPP after COVID-19 vaccination.

The mRNA vaccines against COVID-19 are highly effective, whereas breakthrough infections are occurring. Many clinical trials are in progress and either homologous or heterologous prime-boost formats are proposed.5 While the recent study demonstrated that heterologous booster vaccination induced the neutralizing antibody titres and spike-specific T-cell responses more effectively than homologous booster vaccination,6 further studies are needed to confirm the effectiveness and safety of prime-boost vaccinations.

In the present case, it is unclear that which is the cause of the severe symptoms, a single dose of mRNA-1273 or a robust immune response elicited by heterologous booster vaccination. In addition, there is a possibility that the interaction of COVID-19 vaccine with other drugs plays a role in the development of AEs. Accumulation of similar cases will help to elucidate the underlying mechanisms of AEs caused by COVID-19 booster vaccination.

Funding source
None.

Conflict of Interest
The authors have no conflict of interest to declare.

Acknowledgements
The authors thank the resident doctors, Yuuki Kaida and Aya Hashimoto, for their excellent clinical assistance in emergency medical examination.

Patient consent
The patients in this manuscript have given written informed consent for the publication.

Data availability statement
No data are available.

A. Baba,1,* Y. Maki,2 T. Kanekura,3 H. Tsubouchi4
1Department of Dermatology, Kagoshima City Hospital, Kagoshima, Japan, 2Department of Neurology, Kagoshima City Hospital, Kagoshima, Japan, 3Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, 4Department of Gastroenterology, Kagoshima City Hospital, Kagoshima, Japan
*Correspondence: A. Baba. E-mail: baba-a16@kch.kagoshima.jp

References
1 McMahon DE, Kovarik CL, Damsky W et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry based study. J Am Acad Dermatol 2022; 86: 113–121.
2 Hamarat H, Yorulmaz G, Göñülü EO, Ekim A. Rhabdomyolysis probably induced by influenza vaccine and fibrate therapy, Eur J Rheumatol 2015; 2: 169.
3 Salter B, Jessome M, Tarnopolsky M, Yousuf H. Possible association between rhabdomyolysis and mRNA SARS-CoV-2 vaccination in a patient with RYR1 gene mutation. CMAJ 2022; 194: E252–E256.
4 Kamura Y, Terao T, Akao S, Kono Y, Honma K, Matsue K. Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA-1273 vaccine: a case report. Int J Infect Dis 2022: 117: 322–325.
5 Warkentin L, Zeschick N, Kuhlein T et al. Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study. BMC Infect Dis 2022; 22: 504.
6 Atmar RL, Lyke KE, Deming ME et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022; 386: 1046–1057.

DOI: 10.1111/jdv.18420